+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antiglaucoma Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5319079
  • Report
  • April 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Abbott Healthcare
  • Aerie Pharmaceuticals Inc
  • ALLERGAN
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • MORE
Antiglaucoma Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global antiglaucoma drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the antiglaucoma drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Antiglaucoma Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:
1) By Product Type: Alpha Agonist; Beta Blockers; Prostaglandin Analogs; Combined Medication; Others
2) By Disease Condition Type: Open-Angle Glaucoma; Angle-Closure Glaucoma; Normal-Tension Glaucoma; Congenital Glaucoma; Other Types Of Glaucoma
3) By Type: Hospital Prescription drugs; Over-the counter drugs

Companies Mentioned: Aerie Pharmaceuticals; ALLERGAN; Novartis AG; Abbott Healthcare; Johnson & Johnson

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Healthcare
  • Aerie Pharmaceuticals Inc
  • ALLERGAN
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • MORE
1. Executive Summary

2. Antiglaucoma Drugs Market Characteristics

3. Antiglaucoma Drugs Market Trends And Strategies

4. Impact Of COVID-19 on Antiglaucoma Drugs

5. Antiglaucoma Drugs Market Size And Growth
5.1. Global Antiglaucoma Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Antiglaucoma Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market

6. Antiglaucoma Drugs Market Segmentation
6.1. Global Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Combined Medication
  • Others
6.2. Global Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Open-Angle Glaucoma
  • Angle-Closure Glaucoma
  • Normal-Tension Glaucoma
  • Congenital Glaucoma
  • Other Types Of Glaucoma
6.3. Global Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Prescription drugs
  • Over-the counter drugs
7. Antiglaucoma Drugs Market Regional And Country Analysis
7.1. Global Antiglaucoma Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Antiglaucoma Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Antiglaucoma Drugs Market
8.1. Asia-Pacific Antiglaucoma Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Antiglaucoma Drugs Market
9.1. China Antiglaucoma Drugs Market Overview
9.2. China Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Antiglaucoma Drugs Market
10.1. India Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Antiglaucoma Drugs Market
11.1. Japan Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Antiglaucoma Drugs Market
12.1. Australia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Antiglaucoma Drugs Market
13.1. Indonesia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Antiglaucoma Drugs Market
14.1. South Korea Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Antiglaucoma Drugs Market
15.1. Western Europe Antiglaucoma Drugs Market Overview
15.2. Western Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Antiglaucoma Drugs Market
16.1. UK Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Antiglaucoma Drugs Market
17.1. Germany Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Antiglaucoma Drugs Market
18.4. France Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Antiglaucoma Drugs Market
19.1. Eastern Europe Antiglaucoma Drugs Market Overview
19.2. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Antiglaucoma Drugs Market
20.1. Russia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Antiglaucoma Drugs Market
21.1. North America Antiglaucoma Drugs Market Overview
21.2. North America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Antiglaucoma Drugs Market
22.1. USA Antiglaucoma Drugs Market Overview
22.2. USA Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Antiglaucoma Drugs Market
23.1. South America Antiglaucoma Drugs Market Overview
23.2. South America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Antiglaucoma Drugs Market
24.1. Brazil Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Antiglaucoma Drugs Market
25.1. Middle East Antiglaucoma Drugs Market Overview
25.2. Middle East Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Antiglaucoma Drugs Market
26.1. Africa Antiglaucoma Drugs Market Overview
26.2. Africa Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Antiglaucoma Drugs Market Competitive Landscape And Company Profiles
27.1. Antiglaucoma Drugs Market Competitive Landscape
27.2. Antiglaucoma Drugs Market Company Profiles
27.2.1. Aerie Pharmaceuticals, Inc
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. ALLERGAN
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Novartis AG
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Abbott Healthcare
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Johnson & Johnson
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Antiglaucoma Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Antiglaucoma Drugs Market

30. Antiglaucoma Drugs Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Healthcare
  • Aerie Pharmaceuticals Inc
  • ALLERGAN
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • MORE
Major players in the antiglaucoma drug market are Aerie Pharmaceuticals, Inc., Allergan, Novartis AG, Abbott Healthcare and Johnson & Johnson.

The global antiglaucoma drugs market is expected to grow from $5.76 billion in 2020 to $6.47 billion in 2021 at a compound annual growth rate (CAGR) of 12.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $8.17 billion in 2025 at a CAGR of 6%.

The antiglaucoma drug market consists of sales of antiglaucoma drugs which are used in the treatment of glaucoma. Glaucoma is a disease in which the optic nerve is damaged resulting into irreversible loss of vision and it is often associated with increased pressure of the fluid in eye. The market comprises of segments such as alpha agonists, beta blockers, prostaglandins, combined medication and other. The market does not include the sale of biologics used for the treatment of glaucoma.

To get an antiglaucoma drug approved by the United States Food and Drug Administration (USFDA), drug should have comparable intraocular pressure (IOP) lowering efficacy and benefit-to-hazard ration with respect to the benchmark drug. In 2018, Rhopressa (netarsudil) Ophthalmic Solution by Aerie Pharmaceuticals Inc., was approved by the US FDA considering its ability to lower IOP when compared to benchmarked drugs for glaucoma in the market.

In 2018, Astellas Pharma Inc. acquired Quethera Ltd., a gene therapy company based in the UK. With this acquisition, Astellas has gained authority over Quethera's ophthalmic gene therapy program which focuses on developing novel treatment for ocular diseases such as glaucoma.

Incidence of glaucoma increases with age and due to increase in the geriatric population worldwide, governments are launching initiatives to promote awareness on glaucoma and other eye disorders. For instance, the Vision Health initiative by Centers for Disease Control and Prevention (CDC) in the USA aimed to prevent eye disorders including glaucoma and improve the overall eye health. In Australia, the government funded an eye screening program as part of its Vision 2020 initiative to promote awareness and prevent vision loss among the population suffering from glaucoma and other eye disorders. These government initiatives will stimulate the awareness among the people on glaucoma driving the market for anti-glaucoma drugs.

Anti-glaucoma drugs are facing the risk of patent expiration in the USA and Europe. For instance, travaprost and bimatoprost, which are used in the treatment of glaucoma, will lose its patent in 2021. This will result in the launch of generic form of the drugs that are priced lower than branded drugs thereby reducing the overall market growth.

Companies in the antiglaucoma drugs market are developing combination therapies in the treatment of glaucoma disease due to their ability to lower intraocular pressure in glaucoma patients. Most of the combinations therapies are fixed dose drugs as it offers patient the ease of consumption when compared to non-fixed combinations. Alcon launched a combination drug, Simbrinza which is fixed combination of Brinzolamide and Brimonidine, to help patients in reducing the intake of multiple drugs for glaucoma. Rocklatan is a combination of a rho kinase inhibitor and a prostaglandin analog. Combigan is a combination of beta blocker and alpha agonist. Cosopt is a combination of beta blocker and carbonic anhydrase inhibitor.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Aerie Pharmaceuticals Inc
  • ALLERGAN
  • Novartis AG
  • Abbott Healthcare
  • Johnson & Johnson
  • Merck & Co
  • Genentech Inc.
  • Pfizer Inc.
  • Bayer AG
  • Santen Pharmaceuticals Company Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Valeant Pharmaceuticals International Inc.
  • F. Hoffmann-La Roche Ltd
  • Hoya Corporation
  • Valeant Pharmaceuticals International Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll